Zealand Pharma CEO: "A very busy time for us"

Things are busy at Zealand Pharma, which will launch low blood sugar treatment Zegalogue in the US. According to CEO Emmanuel Dulac, the biotech company is currently delivering on its plans for the launch, and he expects to share news on glepagutide in the second quarter.
Zealand Pharma CEO Emmanuel Dulac | Photo: Stine Bidstrup/ERH
Zealand Pharma CEO Emmanuel Dulac | Photo: Stine Bidstrup/ERH
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN

The publication of Wednesday's quarterly report allows Zealand Pharma's CEO Emmanuel Dulac to close what he calls a historical and excellent quarter.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading